ArticleFrontiers in immunology2024

Corrigendum: Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis.

Fernando Rodríguez-Jorge et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.